Expression of alpha smooth muscle actin in living donor liver transplant recipients

Table 1 Characteristics of patients in tolerance cases and no tolerance cases

Tolerance cases
Pediatric Case	Age at LDLT	Sex	Original disease	Duration of biopsy after cessation of IS	Fibrosis	Positive area of α-SMA (%)	Number of positive cells/5 fields
					(F Stage)		α-SMA	CD68	CD79α
1	5 yr	M	BA	2 yr	0	2.10	377	395	19
(Period of IS: 5 yr 8 mo)				5 yr 4 mo	0	2.03	250	194	3
				6 yr 4 mo	0	2.26	147	422	3
				7 yr 4 mo	0	2.95	243	500	10
2	11 mo	F	BA	4 yr 9 mo	0	1.53	91	264	20
(Period of IS: 3 mo)				7 yr 9 mo	0	2.49	257	552	16
				8 yr 9 mo	1	2.69	398	490	27
				9 yr 9 mo	1	2.76	241	369	21
						2.3 ± 0.46	250.5 ± 102.8	398.2 ± 121.6	14.8 ± 8.7
No tolerance cases
Pediatric Case	Age at LDLT	Sex	Original disease	Duration of biopsy after LDLT	Fibrosis	Positive area of α-SMA (%)	Number of positive cells/5 fields
					(F Stage)		α-SMA	CD68	CD79α
3	11 yr	F	BA	1 yr	0	0.02	9	508	12
				2 yr	0	1.86	134	446	14
4	10 mo	M	BA	1 yr	0	0.47	1	332	8
				1 yr 6 mo	0	0.32	2	424	10
				2 yr	0	0.83	107	525	9
5	7 yr	M	BA	1 yr	0	1.08	178	537	0
				1 yr 6 mo	0	0.63	153	637	7
6	6 yr	F	BA	2 yr	0	0.38	15	92	12
				8 yr	0	0.70	37	202	16
				13 yr	0	1.26	60	432	15
						0.75 ± 0.53	69.6 ± 67.7	413.5 ± 164.2	10.3 ± 4.6
							(mean ± SD)

LDLT: Living donor liver transplantation; IS: Immunosuppression; α-SMA: Alpha smooth muscle actin; BA: Biliary atresia; M: Male; F: Female.